Haemonetics (HAE) Stock Forecast & Price Target

Compare

430 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HAE Analyst Ratings

Moderate Buy

4 Buy

4 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Haemonetics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HAE Stock 12 Month Forecast

Average Price Target

$88.86

▲(7.16% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Haemonetics in the last 3 months. The average price target is $88.86 with a high forecast of $99.00 and a low forecast of $74.00. The average price target represents a 7.16% change from the last price of $82.92.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","100":"$100","60.25":"$60.3","73.5":"$73.5","86.75":"$86.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":99,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$99.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$88.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$74.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,60.25,73.5,86.75,100],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.15,81.60000000000001,83.05000000000001,84.5,85.95,87.4,88.85000000000001,90.3,91.75,93.2,94.65,96.1,97.55,{"y":99,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.15,80.82000000000001,81.49000000000001,82.16000000000001,82.83,83.5,84.17,84.84,85.51,86.18,86.85,87.52,88.19,{"y":88.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,80.15,79.67692307692309,79.20384615384616,78.73076923076924,78.25769230769231,77.78461538461539,77.31153846153846,76.83846153846154,76.36538461538461,75.8923076923077,75.41923076923077,74.94615384615385,74.47307692307692,{"y":74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":78.08,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.77,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$99.00

Average Price Target$88.86

Lowest Price Target$74.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Petusky

Barrington

$90→$93

Buy

12.16%

Upside

Reiterated

01/12/26

Haemonetics price target raised to $93 from $90 at BarringtonHaemonetics price target raised to $93 from $90 at Barrington

Michael Matson

Needham

Hold

―

Reiterated

01/09/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (NASDAQ: RNAC), Rani Therapeutics Holdings (NASDAQ: RANI) and Haemonetics (NYSE: HAE)

Anthony Petrone

Mizuho Securities

$75→$90

Buy

8.54%

Upside

Reiterated

12/17/25

Haemonetics price target raised to $90 from $75 at MizuhoHaemonetics price target raised to $90 from $75 at Mizuho

David Rescott

Robert W. Baird

$99

Buy

19.39%

Upside

Reiterated

12/16/25

Haemonetics price target raised to $99 from $87 at BairdHaemonetics price target raised to $99 from $87 at Baird

Rohin K Patel

J.P. Morgan

$62→$74

Hold

-10.76%

Downside

Reiterated

12/12/25

Haemonetics price target raised to $74 from $62 at JPMorganHaemonetics price target raised to $74 from $62 at JPMorgan

Joanne Wuensch

Citi

$77→$88

Hold

6.13%

Upside

Downgraded

12/11/25

Citi downgrades Haemonetics (HAE) to a Hold

Travis Steed

Bank of America Securities

$75→$90

Hold

8.54%

Upside

Reiterated

12/08/25

Haemonetics (HAE) Gets a Hold from Bank of America Securities

Marie Thibault

BTIG

$85→$88

Buy

6.13%

Upside

Reiterated

11/06/25

Haemonetics price target raised to $88 from $85 at BTIGHaemonetics price target raised to $88 from $85 at BTIG

Andrew Cooper

Raymond James

$105→$78

Buy

-5.93%

Downside

Downgraded

08/11/25

Haemonetics downgraded to Outperform from Strong Buy at Raymond JamesHaemonetics downgraded to Outperform from Strong Buy at Raymond James

David Turkaly

Citizens JMP

$100

Buy

20.60%

Upside

Reiterated

05/20/25

Citizens JMP reiterates Market Outperform Rating on Haemonetics (HAE)Citizens JMP analyst David Turkaly reiterated a Market Outperform rating and $100.00 price target on Haemonetics (NYSE: HAE).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Petusky

Barrington

$90→$93

Buy

12.16%

Upside

Reiterated

01/12/26

Haemonetics price target raised to $93 from $90 at BarringtonHaemonetics price target raised to $93 from $90 at Barrington

Michael Matson

Needham

Hold

―

Reiterated

01/09/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cartesian Therapeutics (NASDAQ: RNAC), Rani Therapeutics Holdings (NASDAQ: RANI) and Haemonetics (NYSE: HAE)

Anthony Petrone

Mizuho Securities

$75→$90

Buy

8.54%

Upside

Reiterated

12/17/25

Haemonetics price target raised to $90 from $75 at MizuhoHaemonetics price target raised to $90 from $75 at Mizuho

David Rescott

Robert W. Baird

$99

Buy

19.39%

Upside

Reiterated

12/16/25

Haemonetics price target raised to $99 from $87 at BairdHaemonetics price target raised to $99 from $87 at Baird

Rohin K Patel

J.P. Morgan

$62→$74

Hold

-10.76%

Downside

Reiterated

12/12/25

Haemonetics price target raised to $74 from $62 at JPMorganHaemonetics price target raised to $74 from $62 at JPMorgan

Joanne Wuensch

Citi

$77→$88

Hold

6.13%

Upside

Downgraded

12/11/25

Citi downgrades Haemonetics (HAE) to a Hold

Travis Steed

Bank of America Securities

$75→$90

Hold

8.54%

Upside

Reiterated

12/08/25

Haemonetics (HAE) Gets a Hold from Bank of America Securities

Marie Thibault

BTIG

$85→$88

Buy

6.13%

Upside

Reiterated

11/06/25

Haemonetics price target raised to $88 from $85 at BTIGHaemonetics price target raised to $88 from $85 at BTIG

Andrew Cooper

Raymond James

$105→$78

Buy

-5.93%

Downside

Downgraded

08/11/25

Haemonetics downgraded to Outperform from Strong Buy at Raymond JamesHaemonetics downgraded to Outperform from Strong Buy at Raymond James

David Turkaly

Citizens JMP

$100

Buy

20.60%

Upside

Reiterated

05/20/25

Citizens JMP reiterates Market Outperform Rating on Haemonetics (HAE)Citizens JMP analyst David Turkaly reiterated a Market Outperform rating and $100.00 price target on Haemonetics (NYSE: HAE).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Haemonetics

3 Months

xxx

Success Rate

28/52 ratings generated profit

Average Return

+1.74%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +1.74% per trade.

1 Year

Anthony PetroneMizuho Securities

Success Rate

32/52 ratings generated profit

Average Return

+8.54%

reiterated a buy rating 28 days ago

Copying Anthony Petrone's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +8.54% per trade.

2 Years

xxx

Success Rate

25/46 ratings generated profit

Average Return

+6.72%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 54.35% of your transactions generating a profit, with an average return of +6.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HAE Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HAE has received 17 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. HAE average Analyst price target in the past 3 months is 88.86.

Each month's total comprises the sum of three months' worth of ratings.

HAE Financial Forecast

HAE Earnings Forecast

Next quarter’s earnings estimate for HAE is $1.25 with a range of $1.18 to $1.28. The previous quarter’s EPS was $1.27. HAE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.

HAE Sales Forecast

Next quarter’s sales forecast for HAE is $331.92M with a range of $327.70M to $336.22M. The previous quarter’s sales results were $327.31M. HAE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year HAE has Performed in-line its overall industry.

HAE Stock Forecast FAQ

What is HAE’s average 12-month price target, according to analysts?

Based on analyst ratings, Haemonetics’s 12-month average price target is 88.86.

What is HAE’s upside potential, based on the analysts’ average price target?

Haemonetics has 7.16% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HAE a Buy, Sell or Hold?

Haemonetics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 4 hold ratings and 0 sell ratings.

What is Haemonetics’s price target?

The average price target for Haemonetics is 88.86. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $99.00 ,the lowest forecast is $74.00. The average price target represents 7.16% Increase from the current price of $82.92.

What do analysts say about Haemonetics?

Haemonetics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of HAE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Haemonetics (HAE) Stock Forecast & Price Target

HAE Analyst Ratings

HAE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Haemonetics

HAE Analyst Recommendation Trends

HAE Financial Forecast

HAE Earnings Forecast

HAE Sales Forecast

HAE Stock Forecast FAQ

Detailed List of Analyst Forecasts